1. Value in Health Regional Issues
Cost-Effectiveness Analysis of Pneumococcal Vaccination with the Pneumococcal Polysaccharide NTHi Protein D Conjugate Vaccine in the Philippines 
Xu-Hao Zhang, PhD, Maria Carmen Nievera, MD, Josefina Carlos, MD, Marilla Lucero, MD, PhD, Gyneth Bibera, MD, Maria Isabel Atienza, MD, Oleksandr Topachevskyi, PGDip, Cecilia Gretchen Navarro-Locsin, MD 
Value in Health Regional Issues 
Volume 3, Pages (May 2014)
DOI: /j.vhri
Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

2. Fig. 1
Markov cohort model design. The cohort model is Markov-based with three exclusive health states: no disease, sequelae, and death. The transition from “no disease” to “sequelae” or “death” is calculated on the basis of this decision tree. In the model, only meningitis can lead to long-term sequelae; meningitis and bacteremia include NTHi meningitis and NTHi bacteremia, respectively; and nonconsulting AOM are accounted for in the quality-of-life impact calculation. AOM, acute otitis media; GP, general practitioner; NTHi, nontypeable Haemophilus influenzae; PCP, primary care physician; PCV13, pneumococcal 13-valent conjugate vaccine; PHiD-CV, pneumococcal polysaccharide nontypeable Haemophilus influenzae protein D conjugate vaccine.
Value in Health Regional Issues 2014 3, DOI: ( /j.vhri )
Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

3. Fig. 2
Tornado diagram for the top 10 most influential parameters of the cost-effectiveness analysis of PHiD-CV vaccination program versus no vaccination (one-way sensitivity analysis) in the Philippines. AOM, acute otitis media; CI, confidence interval; CAP, community-acquired pneumonia; GP, general practitioner; NTHi, nontypeable Haemophilus influenzae; PHiD-CV, pneumococcal polysaccharide nontypeable Haemophilus influenzae protein D conjugate vaccine.
Value in Health Regional Issues 2014 3, DOI: ( /j.vhri )
Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

4. Fig. 3
Univariate sensitivity analysis comparing PHiD-CV with PCV13 in the Philippines. The effect of the nine most influential variables on cost-effectiveness results of the PHiD-CV vaccination program versus the PCV strategy. AOM, acute otitis media; CI, confidence interval; GP, general practitioner; LL, lower limit; NTHi, nontypeable Haemophilus influenzae; PCV13, pneumococcal 13-valent conjugate vaccine; PHiD-CV, pneumococcal polysaccharide nontypeable Haemophilus influenzae protein D conjugate vaccine; QALY, quality-adjusted life-year; UL, upper limit.
Value in Health Regional Issues 2014 3, DOI: ( /j.vhri )
Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

5. Fig. 4
Cost-effectiveness plane of probabilistic sensitivity analysis comparing PHiD-CV with the no-vaccination strategy in the Philippines. PHiD-CV, pneumococcal polysaccharide nontypeable Haemophilus influenzae protein D conjugate vaccine; QALY, quality-adjusted life-year.
Value in Health Regional Issues 2014 3, DOI: ( /j.vhri )
Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

6. Fig. 5
Cost-effectiveness plane of probabilistic sensitivity analysis comparing PHiD-CV with no PCV in the Philippines. PCV13, pneumococcal 13-valent conjugate vaccine; PHiD-CV, pneumococcal polysaccharide nontypeable Haemophilus influenzae protein D conjugate vaccine’ QALY, quality-adjusted life-year.
Value in Health Regional Issues 2014 3, DOI: ( /j.vhri )
Copyright © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions